Genome-wide detection of LOH in prostate cancer using human SNP microarray technology.
Loss of heterozygosity (LOH) of chromosomal regions is crucial in tumor progression. In this study we assessed the potential of the Affymetrix GeneChip HuSNP mapping assay for detecting genome-wide LOH in prostate tumors. We analyzed two human prostate cell lines, P69SV40Tag (P69) and its tumorigenic subline, M12, and 11 prostate cancer cases. The M12 cells showed LOH in chromosomes 3p12.1-p22.1, 11q22.1-q24.2, 19p13.12, and 19q13.42. All of the prostate cases with informative single-nucleotide polymorphism (SNP) markers showed LOH in 1p31.2, 10q11.21, 12p13.1, 16q23.1-q23.2, 17p13.3, 17q21.31, and 21q21.2. Additionally, a high percentage of cases showed LOH at 6p25.1-p25.3 (75%), 8p22-p23.2, and 10q22.1 (70%). Several tumor suppressor genes (TSGs) have been mapped in these loci. These results demonstrate that the HuSNP mapping assay can serve as an alternative to comparative genomic hybridization for assessing genome-wide LOH and can identify chromosomal regions harboring candidate TSGs implicated in prostate cancer.
Dumur
Catherine I
CI
Department of Pathology, Virginia Commonwealth University, Richmond, VA23298-0248, USA.
Dechsukhum
Chavaboon
C
Ware
Joy L
JL
Cofield
Stacey S
SS
Best
Al M
AM
Wilkinson
David S
DS
Garrett
Carleton T
CT
Ferreira-Gonzalez
Andrea
A
D000328:Adult; D002874:Chromosome Mapping; D016678:Genome; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D020641:Polymorphism, Single Nucleotide; D014407:Tumor Cells, Cultured